Alpha Cognition Inc. ( $ACOG.V $ACOGF ) is developing medicines for the treatment of ALS, Alzheimer's and other under-served neurodegenerative diseases.
One of the drugs they are developing, Alpha-1062 helps with the cognitive effects of Alzheimer's.
A-1062 is very similar to a drug that was approved in the mid-2000s (developed by J&J) but has serious side effects that are hard for most to bear. $ACOG is developing their version of the drug because adherence to J & J version was low and therefore was consisting helping with long-term outcomes.
It has been found that if patients do adhere to drugs like A-1062, 80% of Alzheimer's patients that are galantamine-treated live independently versus 30% of untreated patients at 36 months ( watch here: https://fb.watch/9mwQPOULdq/ )
Additionally, $ACOG is developing Alpha-602 which is a progranulin gene therapy drug.
A-602 could possibly become a curative option for ALS disease.
$ACOG is currently trading at $1.17, MC is ~$72M
One of the drugs they are developing, Alpha-1062 helps with the cognitive effects of Alzheimer's.
A-1062 is very similar to a drug that was approved in the mid-2000s (developed by J&J) but has serious side effects that are hard for most to bear. $ACOG is developing their version of the drug because adherence to J & J version was low and therefore was consisting helping with long-term outcomes.
It has been found that if patients do adhere to drugs like A-1062, 80% of Alzheimer's patients that are galantamine-treated live independently versus 30% of untreated patients at 36 months ( watch here: https://fb.watch/9mwQPOULdq/ )
Additionally, $ACOG is developing Alpha-602 which is a progranulin gene therapy drug.
A-602 could possibly become a curative option for ALS disease.
$ACOG is currently trading at $1.17, MC is ~$72M